Insider Files Form 144 for IONS — 10,000 Shares Proposed Sale ($503.7K)
Rhea-AI Filing Summary
Ionis Pharmaceuticals insider sale notice: This Form 144 shows a proposed sale of 10,000 shares of Ionis common stock through Stifel Nicolaus & Company, with an aggregate market value of $503,671. The filing reports the shares were acquired as restricted stock units on 01/15/2019 (16,802 units originally) and payment was in cash. The filer previously sold 10,000 shares on 08/05/2025 for $428,593. The company has 159,391,229 shares outstanding, so the proposed sale represents approximately 0.0063% of outstanding shares. The filer attests there is no undisclosed material information.
Positive
- Complete disclosure of broker, quantity, acquisition date, and prior sale within three months
- Insider attestation asserts no undisclosed material information, aligning with compliance expectations
Negative
- Insider sale reported (10,000 shares), which some investors monitor as a potential signal despite being small
- No Rule 10b5-1 plan date provided in the remarks section, so planned-trading status is not stated
Insights
TL;DR: Routine Form 144 filing reporting an insider sale of 10,000 shares valued at $503,671; small relative to outstanding stock.
The filing documents a proposed brokered sale of 10,000 Ionis shares via Stifel Nicolaus with an aggregate market value of $503,671. The securities were acquired as restricted stock units on 01/15/2019 and previously a sale of 10,000 shares occurred on 08/05/2025 for $428,593. Given 159,391,229 shares outstanding, the proposed sale is roughly 0.0063% of the float, which is immaterial from a market-cap perspective. The filing includes the standard insider attestation regarding material nonpublic information.
TL;DR: Filing reflects compliance with Rule 144 disclosure for an insider sale; nothing in the record indicates regulatory or governance concerns.
The notice provides required disclosure elements: broker name and address, quantity, aggregate market value, acquisition date and nature (restricted stock units), and recent sales within three months. The inclusion of the prior sale on 08/05/2025 and the attestation statement supports procedural transparency. There are no statements of plan adoption dates for Rule 10b5-1 in the remarks section.